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ttp://dx.doi.org/10.1016/j.jmoldx.2013.06.001Congenital adrenal hyperplasia, due to 21-hydroxylase deﬁciency (21-OHD) is an autosomal recessive
disorder of adrenal steroidogenesis caused by mutations in the CYP21A2 gene. Direct comparison of
established and novel methodologies of CYP21A2 genetic analysis in a large cohort representing a wide
range of genotypes has not been previously reported. We genotyped a cohort of 129 unrelated patients
with 21-OHD, along with 145 available parents, using Southern blot (SB) analysis, multiplex ligation-
dependent probe ampliﬁcation (MLPA), PCR-based restriction fragment length polymorphism (RFLP)
analysis, multiplex minisequencing and conversion-speciﬁc PCR, duplication-speciﬁc ampliﬁcation, and
DNA sequencing. CYP21A2 genotyping identiﬁed four duplicated CYP21A2 genes (1.53%) and 79 chimeric
CYP21A1P/CYP21A2 genes (30.15%). Parental SB data were essential for determining the CYP21 haplo-
type in three cases, whereas PCR-based RFLP analysis was necessary for MLPA results to be accurately
interpreted in the majority of cases. The comparison of different methods in detecting deletion and
duplication showed that MLPA with PCR-based RFLP was comparable with SB analysis, with parental data
of 100% sensitivity and speciﬁcity. DNA sequencing was required for the identiﬁcation of 16 (6.1%) rare
point mutations and determination of clinically signiﬁcant chimera junction sites. MLPA with PCR-based
RFLP analysis is an excellent substitute for SB analysis in detecting CYP21A2 deletion and duplication and
a combination of MLPA, PCR-based RFLP, duplication-speciﬁc ampliﬁcation, and DNA sequencing is
a convenient and comprehensive strategy for mutation analysis of the CYP21A2 gene in patients with
21-OHD. (J Mol Diagn 2013, 15: 745e753; http://dx.doi.org/10.1016/j.jmoldx.2013.06.001)Supported by the Intramural Research Programs of the NIH, National
Institute on Aging, the Clinical Center, and the Eunice Kennedy Shriver
National Institute of Child Health and Human Development.
D.P.M. serves as a Commissioned Ofﬁcer in the United States Public
Health Service.
Z.X. and W.C. contributed equally to this work.Congenital adrenal hyperplasia [(CAH) OMIM 201910] is
a group of autosomal recessive disorders characterized by
impairment of cortisol biosynthesis, with or without im-
pairment of aldosterone biosynthesis,1 and approximately
95% of cases are due to 21-hydroxylase deﬁciencyogy
Xu et al(21-OHD).2 CAH is manifested in a variety of clinical
severities comprised of three subtypes: i) classic salt
wasting, ii) classic simple virilizing, and iii) nonclassic
(mild or late onset) forms. The incidence of classic CAH
worldwide ranges from 1 in 10,000 to 1 in 20,000 births.3
The steroid 21-hydroxylase gene,CYP21A2, is located in the
human leukocyte antigen class III region on chromosome
6p21.3, closely adjacent in tandem with three other genes
(serine/threonine kinase RP, complement C4, and tenascin
TNX), forming a genetic module termed RCCX (RP-C4-
CYP21-TNX).4 The RCCX module shows a high homology
between the functional genes (RP1, CYP21A2, and TNXB) and
the corresponding pseudogenes (RP2, CYP21A1P, and TNXA),
leading to gene conversions5 and gene deletions due to homol-
ogous recombination, which inactivate the functional genes.
Molecular analysis of CYP21A2 gene is of great impor-
tance to understanding the etiology of 21-OHD, both in basic
science and in clinical diagnosis.1 Approximately 95% of
defective CYP21A2 genes seen in CAH fall into three cate-
gories6: i) approximately 65% to 70% are deleterious muta-
tions derived from pseudogene CYP21A1P due to small gene
conversions, including In2G [IVS-13 A/C->G (28%)],
p.I172N (9%), p.V281L (9%), p.Q318X (4%), p.R356W
(4%), E6 cluster [p.I235N, p.V236E, p.M238K (4%)],
p.G110fx21 (3%), p.P30L (2%), and p.L307fx15 (1%)2,7; ii)
approximately 5% are spontaneous point mutations; and iii)
approximately 25% to 30% are large gene rearrangements
generated by unequal meiotic crossing over.8e13
Large CYP21A2 gene rearrangements have been tradition-
ally detected by Southern blot (SB) analysis.10,14,15 Other
strategies including PCR-based restriction fragment length
polymorphism (RFLP)16e18 and the real-time quantitative
PCRebased method for CYP21A2 copy number detection9,19
have also been described; however, only 82% of studied
subjects showed agreement between SB analysis and the
quantitative PCR-basedmethod.9 Recently,multiplex ligation-
dependent probe ampliﬁcation (MLPA) has been increasingly
used for identiﬁcation of CYP21A2 gene deletion and dupli-
cation,11,20 suggesting that MLPA may replace SB analysis as
an efﬁcient strategy to identify gene copy number. Coeli et al21
combinedMLPAandSB in the genetic analysis of 20Brazilian
patients with 21-OHD. However, to our knowledge, a study
comparing SB and MLPA in the evaluation of CYP21A2 gene
rearrangements in a large cohort of patients representing
diverse genotypes with 21-OHD has not been performed.
Moreover, distinction among CYP21A2 deletions is clinically
signiﬁcant. Certain junction sites of CYP21A1P/CYP21A2
chimera have been associated with a milder phenotype, the so-
called attenuated chimera.8 In addition, contiguous deletion of
CYP21A2 and TNXB has been associated with Ehlers Danlos
syndrome in a signiﬁcant subset of CAH patients.22 Identiﬁ-
cation of these clinically signiﬁcant chimeras has been incor-
porated into our mutation analysis strategy.
An additional challenge in the molecular evaluation of
CYP21A2 results from the proximity and homology (98% in
exons and 96% in introns15) of a pseudogene, CYP21A1P.746Impure PCR products can be potentially generated by ampli-
fying the pseudogene, with detection of pseudogenemutations
rather than functional gene mutations. To address this issue,
several methods have been developed in the past three de-
cades, such as high-resolution melting curve,23 locus-speciﬁc
PCR,9,13,24,25 denaturing high-performance liquid chroma-
tography analysis,26 and multiplex minisequencing.25 These
methods adopt a common core strategy based on the known
mutations andhave some limitationswith themaximumoverall
sensitivity of mutation detection achieved, which is reported to
range from 90%9,27 to 95%.28
We sought to establish a multistep deﬁnitive strategy
to perform a convenient and comprehensive mutation
analysis of the CYP21A2 gene for patients with 21-OHD.
Thus, we compared data from SB, MLPA, and multiplex
minisequencing and conversion-speciﬁc PCR (MMCP) in
129 unrelated patients with 21-OHD, and we included the
identiﬁcation of clinically signiﬁcant chimeras.
The strategy presented here provides an accurate and
inclusive genetic picture of the CYP21A genes in each pa-
tient with 21-OHD, and thus represents a useful tool in the
diagnosis and management of CAH.
Materials and Methods
Characterization of the Patients
Patients with 21-OHD underwent comprehensive clinical29
and genetic30 evaluations as part of an ongoing observa-
tional study at theNational Institutes ofHealth Clinical Center
(http://clinicaltrials.gov/ct2/show/NCT00250159?termZNCT
00250159&rankZ1, last accessed February 1, 2013). DNA
was obtained fromperipheral blood leukocytes using standard
methodology. All studies were approved by the Eunice
Kennedy Shriver National Institute of Child Health and
Human Development Institutional Review Board and the
MedStar Health Institutional Review Board. All patients and
their family members gave informed consent for DNA anal-
ysis, and all minors 8 years old gave their assent.
SB Analysis and MMCP
To genotype the copy number variation of RCCX modules,
SB was performed for unrelated patients with 21-OHD and
their parents using TaqI and PshAI (both from New England
BioLabs, Ipswich, MA) as previously described.30 MMCP
analysis was conducted to identify the 12 most common
CYP21A2 mutations, 12 single nucleotide polymorphic
markers, and the 30-kb deletion, as previously described.30
MLPA
MLPA, a rapid and high-throughput technique for copy
number quantiﬁcation31 was performed using the SALSA
MLPA Kit P050-B2 CAH (MRS Holland, the Netherlands)
according to the manufacturer’s recommendations. Ampli-
ﬁcation products were run on ABI Genetic Analyzer 3130xljmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Primers Used for PCR and Sequencing
Primer Sequence Location Genes Purpose Reference
seq1 50-CCCCAAAACAGTCTACACAG-30 50UTR CYP21A2 and CYP21A21P Sequencing Present study
seq2 50-GGCCCGAATTTCTGAGTCA-30 Exon1 CYP21A2 and CYP21A21P Sequencing Present study
seq3 50-TGTGGTGGTGCTGAACTC-30 Exon2 CYP21A2 and CYP21A21P Sequencing Present study
seq4 50-AGCAGGGAGTAGTCTCCC-30 Exon3 CYP21A2 (G110)* Sequencing Present study
seq5 50-GCTTTCCAGAGCAGAGACC-30 Exon3 CYP21A1P (G110fx21)* Sequencing Present study
seq6 50-TTCTGTGAGGTAAGGCTGG-30 Exon3/Intron3 CYP21A2 and CYP21A21P Sequencing Present study
seq7 50-TACTGTGAGAGGCGAGGCTGA-30 Intron3 CYP21A2 and CYP21A21P Sequencing Present study
seq8 50-TTTCTCAGGGTGAGGACCTG-30 Exon5/Intron5 CYP21A2 and CYP21A21P Sequencing Present study
seq9 50-CCTCACTCAGCTCTGAGCACT-30 Intron7 CYP21A2 and CYP21A21P Sequencing Present study
seq10 50-TTGTGCCCTTAGCCTTGC-30 Exon8 CYP21A2 and CYP21A21P Sequencing Present study
seq11 50-TTTCCTCACTCATCCCCAAC-30 Intron8 CYP21A2 and CYP21A21P Sequencing Present study
seq12 50-AAGAACTCCAGAGCTCTGGC-30 Exon10 CYP21A2 and CYP21A21P Sequencing Present study
seq13 50-TCTCAGCTTCATTTCCGTGA-30 30UTR CYP21A2 and CYP21A21P Sequencing Present study
CYP779f 50-AGGTGGGCTGTTTTCCTTTCA-30 50 end CYP21A2 and CYP21A21P PCR (sense) 18
Tena32F 50-CTGTGCCTGGCTATAGCAAGC-30 Intron32 TNXB PCR (antisense) 18
21BF1 50-CCCAGGTGGGGGCGGACACTA-30 50 end CYP21A2 PCR (sense) 32
XAy 50-ACTCCAGGTGGGAGTCAAGAA-30 120-bp del TNXA PCR (antisense) Present study
*Primer seq4 and seq5 are speciﬁc to wild-type and mutant of p.G110, respectively.
yXA is reverse complementary to the XA-speciﬁc antisense primer32.
Molecular Diagnosis of CAH(Applied Biosystems, Foster City, CA). The kit is designed
to detect deletions and duplications of one or more exons of
CYP21A and TNX genes, and contains ﬁve probes for
CYP21A2 (p.P30L, p.G110fsX21, p.I172N, E6cluster, and
p.Q318X mutations) and three CYP21A1P-speciﬁc probes.
PCR-Based RFLP
To genotype large gene deletions at the centromeric tail of
the RCCX module, primers CYP779f and Tena32F18Table 2 Summary of Different Methods for Genotyping CYP21A2 Gene
Method Targeted mutations Advantage
SB 1. Deletion and duplication 1. Informative for the whol
MLPA 1. Deletion and duplication 1. Convenient
2. Point mutations 2. Rapid
3. High-throughput
4. Low DNA quantity require
5. Indicates junction sites o
PCR-RFLP 1. Deletion 1. Convenient
2. Low DNA quantity and qu
MMCP 1. Deletion and duplication 1. Convenient
2. Known point mutations 2. Rapid
3. High-throughput
Sequencing 1. Point mutations 1. Detects point mutations
2. Determines junction sites
MLPA, multiplex ligation-dependent probe ampliﬁcation; MMCP, multiplex min
fragment length polymorphism analysis; RCCX, RP-C4-CYP21-TNX; SB, Southern bl
The Journal of Molecular Diagnostics - jmd.amjpathol.org(Table 1) were used to amplify a fragment of 8515-bp by
using the Expand Long-Range dNTPack (Roche Applied
Science, Indianapolis, IN). The reaction condition followed
the manufacturer’s recommendations, except for using an
annealing temperature of 62C. The 8.5 kb PCR products
were puriﬁed with QIAquick PCR Puriﬁcation Kit (Qiagen,
Valencia, CA) and were then digested with 20 U TaqaI
(New England BioLabs) for 2.5 hours at 37C followed by
15 minutes at 85C. Digested products were electrophoresed
for 16 hours on a 0.8% agarose gel.s
Disadvantage
e RCCX module 1. Laborious
2. Radioactive biohazard
3. Requires high quantity and good quality DNA
4. RCCX trimodule causes densitometric error
5. Cannot determine junction sites of chimeras
6. Parental data often required
1. Duplication masks deletion.
2. Signals are sensitive to quality of DNA and
probe binding.
3. Requires extensive knowledge of RCCX module
d 4. Difficult to determine phase of deletion/
duplication
f chimeras 5. Results must be confirmed by other methods
1. Cannot determine junction sites of chimeras
ality required
1. Cannot detect novel mutations
2. Cannot determine phase of deletion/
duplication
3. Some results are equivocal
1. Risk of false negative/positive results
of chimeras 2. Primers must be carefully designed
i-sequencing and conversion-speciﬁc PCR; PCR-RFLP, PCR-based restriction
ot.
747
Figure 1 Southern blot analysis of RCCX module in two representative
patients and their respective parents. A: Schematic of a typical RCCX
bimodule allele. Dashed boxes denote pseudogenes; short vertical lines, TaqI
restriction sites; numbers, fragment sizes (in kb). B and C: TaqI and PshAI
Southern blots. Enzyme digested fragments with size (in kb) correspond to
target gene(s). D: Densitometric ratios were measured in Southern blots. The
ratios indicate gene dosages, which can be used to infer gene arrangement.
Columns 1 and 1F represent patient 1 and the father, respectively; columns 2,
2M, and 2F represent patient 2, the mother, and the father, respectively.
Xu et alSequencing CYP21A2 and Chimeric CYP21A1P/CYP21A2
Genes
To identify point mutations in the CYP21A2 and chimeric
CYP21A1P/CYP21A2 genes, another aliquot (50 mL PCR
product [CYP779f/Tena32F]) was obtained for each sample.
After agarose gel discrimination, the PCR product was puri-
ﬁed with 1 U of shrimp alkaline phosphatase (USB, Cleve-
land, OH) and 3.5 U of exonuclease I (USB), followed by
sequencing using Big Dye Terminator V3.1 (Applied Bio-
systems) and inner sequencing primers (Table 1) on ABI
Genetic Analyzer 3100xl (Applied Biosystems). Results were
aligned with the reference CYP21A2 (ENSG00000206338)
and CYP21A1P (ENSG00000204338) sequences.
21BF1/XA Ampliﬁcation to Identify Duplicated
CYP21A2 Gene
Primers 21BF1 and XA (Table 1) were used to amplify
a 5.6-kb fragment by Expand Long-Range dNTPack for
identiﬁcation of duplicated CYP21A2 genes telomeric to the
TNXA gene. The reaction conditions followed the manu-
facturer recommendations except for using an annealing
temperature of 58C and addition of 2% DMSO. Primer
21BF1 matched the 50 end of the CYP21A2 gene exclu-
sively,33 and primer XA was located in the TNXA-speciﬁc
region containing a 121-bp deletion closing the reading
frame.34 The 5.6-kb PCR products were then puriﬁed and
sequenced as described above.
Results
Methods Comparison
SB analysis, MLPA, PCR-based RFLP, DNA sequencing,
and MMCP were performed on 129 unrelated patients with
21-OHD and 145 available parents. Based on our analysis of
the cohort, each method had advantages and disadvantages
(Table 2). Parental SB data were essential for determining
the CYP21 haplotype in three cases (2.32%), two of which
involved a combination of duplication and deletion.
A multistep strategy was necessary to accurately deﬁne
genotype, illustrated by two representative families (Figure 1).
The SB densitometric ratio of CYP21A2 versus CYP21A1P in
patient 1 was 2:1 (Figure 1, B and D), consistent with MLPA
data (Figure 2B). This observation thus led to an interpretation
of no CYP21A2 gene deletion/duplication in patient 1.
However, a 3.2-kb CYP21A1P-speciﬁc band was observed
in PCR-based RFLP, indicating CYP21A2 gene deletion
(Figure 2D) and we obtained a positive ampliﬁcation using
primers 21BF1/XA (Figure 2E), suggesting CYP21A2 gene
duplication.DNAsequencing identiﬁedp.P30L, p.G110fsX21,
and p.I172Nmutations inheterozygosity inCYP779f/Tena32F
amplicon and p.I172N, E6cluster, p.V281L, and p.L307fx15
mutations in 21BF1/XA amplicon from patient 1. Therefore,
as shown in Figure 2F, the genotype of patient 1 was two748TNXB-adjacent CYP21A2 genes (one CH-1 chimera8 and
one with p.I172N), and one TNXA-adjacent CYP21A2 gene
(carrying p.I172N, E6cluster, p.V281L, and p.L307fx15
mutations), consistent with MMCP data.
Patient 2 SB showed a weaker band of CYP21A2 gene
than CYP21A1P gene indicating a possible CYP21A2 gene
deletion, yet the bands were too dense to measure the exact
ratios, rendering an ambiguous interpretation (Figure 1).
The SB on the parents of patient 2 revealed the ratios of
CYP21A2 versus CYP21A1P 2:3 in the mother and 2:2 in
the father, illustrating that parental SB data were essential
for determining the CYP21 haplotype (Figure 1). MLPA
showed that patient 2 had two dosages of CYP21A2 gene
(Figure 2C). No CYP21A2 gene deletion and duplication
was observed in the PCR-based RFLP (Figure 2D) or
21BF1/XA ampliﬁcation (Figure 2E). DNA sequencing of
the CYP779f/Tena32F amplicon of patient 2 identiﬁed the
p.V281L mutation in homozygosity, consistent with the
MMCP data. Thus, we inferred that patient 2 carried two
dosages of the CYP21A2 gene, both with the p.V281L
mutation, and four dosages of CYP21A1P gene. In both
cases, accurate genotyping required PCR-based RFLP injmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 MLPA, PCR-based RFLP, and PCR-based
duplication analysis of two representative patients
and their respective parents. A: Scheme shows MLPA
probes and PCR primers. Dashed boxes indicate
pseudogenes; white arrows, primers used to amplify
duplicated CYP21A2 gene; black arrows, PCR-based
RFLP primers; short vertical lines, TaqaI restriction
site of CYP779f/Tena32F ampliﬁed products, with
numbers showing the fragment size (in kb); vertical
arrows, hybridization sites of the MLPA probes. ex,
exon; int, intron; UTR, untranslated region. B and C:
Normalized MLPA data of families of patient 1 and
patient 2 with probes on x axis. Columns correspond
to normalized electropherogram peak areas calcu-
lated using Coffalyser software. Diamonds denote
results of point mutations; circles denote results of
chimeric genes. Ratio values (y axis) between 0.7 and
1.3 (dashed lines) indicate two copies, bottom
dashed lines (one copy) and top dashed lines (two
copies). 1 and 1F represent patient 1 and the father,
respectively. 2, 2M, and 2F represent patient 2, the
mother, and the father, respectively. D: Electrophe-
rogram of TaqaI digested CYP779f/Tena32F ampliﬁed
products. Target fragments are labeled with gene
names and size.L, CYP21A2 deletion on one allele;
þ, no deletion; M, 1 kb DNA ladder; C1eC3, controls
with two, one, and no CYP21A2 deletions, respec-
tively. The3.2 kb band for the CYP21A1Pgenewas not
detected in samples 1F, 2, 2M, and 2F, which indi-
cated no CYP21A2 deletion; sample 1 shows one 3.2
kb band for CYP21A1P gene, conﬁrming CYP21A2
deletion. E: Electropherogram of products of
duplication-speciﬁc ampliﬁcationusingprimer21BF1
andXA;no ampliﬁcation is observedwithout CYP21A2
duplication. A positive 5.6 kb band for samples 1 and
1F indicates CYP21A2 duplication. The faint bands
shown in samples 2, 2M, 2F, and C3 result from
unspeciﬁc ampliﬁcation. F: Genotyping results of
patient 1 and 2. The following 21A2, 21A1P, XA, and
XB stand for CYP21A2, CYP21A1P, TNXA, and TNXB,
respectively. CYP21A2 genes identiﬁed with point
mutations are set bold and underlined.
Table 3 Comparison of Different Methods Used to Detect
Deletion and Duplication of the CYP21A2 Gene
Detection
Combined
methods* SBy
MLPA and
PCR-RFLP MMCP
Deletion on one allele 49 49 49 43
Deletion on two alleles 15 15 15 15
Duplication 4 4 4 3
No deletion and duplication 65 65 65 58
Status unknown 0 0 0 13
Numbers of detected samples are shown.
*Final results were given based on all assays used.
yBased on proband and parental data.
Molecular Diagnosis of CAHcombination with MLPA and parental data for SB due to
duplication and/or deletion involving the CYP21 genes.
We compared data from SB analysis of probands and
available parents, MLPA with PCR-based RFLP and
MMCP in detecting CYP21A2 gene deletion and duplication
(Table 3). We found 100% agreement between SB with
parental data and MLPA with PCR-based RFLP, both
yielding authentic results, whereas MMCP showed 91.6%
sensitivity (76 of 83 alleles; 95% conﬁdence interval [CI] 86
to 98) and 88.8% speciﬁcity (159 of 179 alleles; 95% CI 84
to 93) because it missed one duplicated CYP21A2 gene, and
the equivocal results were also observed in 13 individuals.
Indeed, both SB analysis and MLPA with PCR-based RFLP
identiﬁed CYP21A2 gene deletion on one allele in six of
these 13 individuals.
Mutation Analysis and Genotyping Strategy Proposal
The CYP21A2 genotyping results for all 129 individuals
revealed a wide spectrum of mutations (Table 4), and eachThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmutation or deletion was conﬁrmed by at least two methods.
Of 262 CYP21A2 genes, four (1.53%) were duplicated
CYP21A2 genes and 79 (30.15%) were chimeric CYP21A1P/
CYP21A2 genes. Of the 79 chimeras, 76 truncated the
functional CYP21A2 gene, whereas the other three were of
attenuated form associated with less severe phenotype.8
Among the nine most common mutations, In2G (23.57%),749
Table 4 CYP21A2 Mutations Found in 129 Unrelated Patients
with 21-OHD
Type Allele No.
Frequency in
262 alleles (%)
Classic chimeric CYP21A1P/CYP21A2*
CH-1 30 11.45
CH-2 0 0.00
CH-3 4 1.53
CH-5 29 11.07
CH-6 0 0.00
CH-7 0 0.00
CH-8 13 4.96
Total 76 29.01
Attenuated chimeric CYP21A1P/CYP21A2*
CH-4 3 1.15
CH-9 0 0.00
Total 3 1.15
Total chimeric CYP21A1P/CYP21A2
79 30.15
Most common mutationsy
In2G 62 23.66
V281L 47 17.94
I172N 36 13.74
Q318X 11 4.20
R356W 9 3.44
L307fx15 6 2.29
E6cluster 5 1.91
G110fsX21 2 0.76
P30L 1 0.38
Other point mutations
16 6.11
CYP21A2 duplications
4 1.53
*Chimeric types were assigned according to Chen et al.8
yNomenclature at the protein level is based on conventional codon
numbering. Nomenclature at the cDNA level, based on ENST00000418967,
is as follows: P30L (c.92C>T), In2G (c.293-13A/C>G), G110fsX21 (c.332_
339del), I172N (c.518T>A), D183E (c.552C>G), D234D (c.705T>C),
E6cluster [I236N (c.710T>A), V237E (c.713T>A), M239K (c.719T>A)],
V281L (c.844G>T), L307fx15 (c.923_924insT), Q318X (c.955C>T), and
R356W (c.1069C>T); 21-OHD, 21-hydroxylase deﬁciency.
Figure 3 Molecular analysis strategy of the CYP21A2 gene in CAH
patients. The target of this strategy is to identify mutations in deleted,
duplicated, and normal CYP21A2 genes. Final genotyping result of each
patient is given in the bottom row, including chimera type of CYP21A1P/
CYP21A2 genes and point mutations in normal and duplicated CYP21A2
genes. Rectangles denote the methods; ovals, results from the upstream
methods; diamonds, results of point mutations; circles, results of chimeric
genes. The junction site of each chimeric gene was identiﬁed based on data
from MLPA (dashed lines) and sequencing CYP779f/TenaF amplicon.
Xu et alp.V281L (17.87%), and p.I172N (13.69%) were most
frequent. Sixteen uncommon mutations were identiﬁed by
sequencing, accounting for 6.11% allele frequency.
Based on our results, we developed a comprehensive
strategy for the genetic analysis of the CYP21A2 gene inCAH
patients (Figure 3). First, MLPA with PCR-based RFLP
should be performed on each patient to identify gene dele-
tion and/or duplication. Sequencing CYP779f/Tena32F and/
or 21BF1/XA amplicon is then conducted to identify point
mutations. The junction site of the chimeric CYP21A1P/
CYP21A2 gene is deﬁned by the identiﬁed pointmutations and
the MLPA data.
Discussion
CAH due to 21-OHD is a life-threatening disease, and
neonatal screening for CAH is performed in theUnited States.750The molecular diagnosis is useful in evaluating borderline
cases3 but is fraught with challenges. Our study is the ﬁrst
comprehensive comparison of various existing methodolo-
gies that has been proposed for CYP21A2 mutation analysis.
In our study, we conducted extensive mutation analysis of
the CYP21A2 gene for 129 unrelated patients with 21-OHD,
using SB analysis, MLPA, PCR-based RFLP, MMCP, and
DNA sequencing. We found that MLPA with PCR-based
RFLP when combined with duplication-speciﬁc ampliﬁca-
tion and DNA sequencing is the preferred methodology, and
this provides an accurate and comprehensive approach to
the molecular diagnosis of CAH due to 21-OHD.
Our extensive comparison of various methodologies
revealed that MLPA in combination with PCR-based RFLP
is comparable with SB in detecting the CYP21A2 gene
deletion and duplication. The sole use of MLPA method-
ology has limitations and it requires a deep knowledge of
CYP21A2 gene arrangements. It should be noted that
a mutation or polymorphism in a probe-binding region could
cause a reduction in the relative peak area, even when it is not
located exactly on the ligation site. Another major limitation
of MLPA is that the probes do not determine the phase of the
deletion and duplication. Thus, it is possible that adjacent
probes with apparently reduced signals are on different
chromosomes or represent noncontiguous point mutations.
Additionally, based on our experience, some probes of the
MLPA kit P050-B2 CAH (MRC-Holland, Holland, the
Netherlands) are extremely sensitive to DNA quality and
small changes in experimental manipulation. Our analysis
of patient 1 provides evidence that MLPA is prone to
producing an inconclusive result without PCR-based RFLP
data when CYP21A2 deletion is masked by duplication.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Molecular Diagnosis of CAHThus, as suggested by Concolino et al,20 for most if not all
cases, MLPA alone is not able to yield accurate results, and
thus a combination of MLPA and PCR-based RFLP should
be used for the analysis of CYP21A2 gene deletion and
duplication in patients with 21-OHD.
SB analysis is the reference standard in detection of large
gene arrangement in the RCCX module.10,14,15 However,
densitometric screening of fragments is prone to error for an
allele with a trimodular RCCX, which is estimated to occur in
2.7% to 7% of patients.30,35 Our analysis of SB data showed
that in three out of 129 cases (2.32%), two of which involved
duplications and deletions, and parental data were necessary
for accurate interpretation. Because SB is laborious, time-
consuming, involves the use of radioisotopes, and requires
a relatively large quantity of DNA sample, alternative meth-
odologies are preferable. In our comparison of SB, MLPA
with PCR-based RFLP, and MMCP, we found that SB and
MLPA with PCR-based RFLP are impressively equivalent
and more sensitive than MMCP in detecting CYP21A2 gene
deletion and duplication. The combined MLPA with PCR-
based RFLP method shows great advantage in comparison
with SB because it requires a smaller amount of genomic
DNA (25 to 250 ng) and no use of radioisotopes. None of our
cases required parental samples for interpretation using the
combined MLPA with PCR-based RFLP method. Moreover,
MLPA also indicates particular pointmutations (c.1-126C>T,
c.1-112G>A, c.1-110T>C, c.1-103A>G, p.G110fsX21,
p.I172N, p.I236N, p.V237E, p.M239L, and p.Q318X), as
these mutations are located in the probe-binding regions.
MLPA with PCR-based RFLP, and is, therefore, is an infor-
mative, convenient, and sensitive tool for detection of deletion
and duplication, and the junction site of each chimera could be
preliminarily predicted based on the contiguous probes.8
DNA sequencing is often needed in CYP21A2 genotyping,
especially for identiﬁcation of uncommon mutations. Pre-
vious studies8,13 show that analysis of the junction sites of
chimeric CYP21A1P/CYP21A2 genes may be useful in the
clinical diagnosis and genetic counseling of patients with
21-OHD because some chimeras attenuate the severity of the
CAH phenotype. Sequencing of the CYP21A2 gene, espe-
cially in cases with a chimeric CYP21A1P/CYP21A2 gene,
may be necessary to localize the junction site. Moreover,
three of the common mutations (p.P30L, p.V281L, and
p.R356W) cannot be detected by the MLPA kit P050-B2
CAH (MRC-Holland), underlining the utility of sequencing.
Duplicated CYP21A2 genes in RCCX modules have been
found in previous studies.30,35,36 In the present study,
primers 21BF1 and XA were used for the detection of
duplication, and the amplicon was then sequenced to iden-
tify point mutation in the duplicated CYP21A2 gene. The
mutation carrier ship in the duplicated CYP21A2 gene is of
clinical importance through modulation of phenotypes. An
alternative PCR method to detect a duplicated CYP21A2
gene was previously proposed.35 However, the sense primer
used for the CYP21A2 gene in this methodology is located
at the sequence of wild-type p.G110fsX21, suggesting thatThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthese primers will not work if the duplicated CYP21A2 gene
carries a p.G110fsX21 mutation.
In our study, we propose a comprehensive strategy for
accurate mutation analysis of the CYP21A2 gene: MLPA,
PCR-based RFLP, duplication-speciﬁc ampliﬁcation, and
DNA sequencing. Vrzalová et al11 used a similar strategy to
study chimeric CYP21A1P/CYP21A2 genes in a CAH cohort.
However, to amplify the CYP21A1P/CYP21A2 genes, they
used CYP21A1P-speciﬁc AF1 and CYP21A2-speciﬁc 21BR
primers, located in the 50 end of CYP21A1P gene and the 30
untranslated region ofCYP21A2 gene, respectively. Our recent
study,37 uncovers that 21BR primer is not CYP21A2 speciﬁc
becauseCYP21A1P-speciﬁc polymorphisms were observed in
high frequency (5 of 28 alleles) in the primer-binding region.
Thus, ampliﬁcation of primers AF1/21BR will undoubtedly
produce false-negative results. Other most commonly used
PCR primers are two overlapping CYP21A2-speciﬁc primer
pairs, one located in the 50 end and exon 3 (wild-type of
p.G110fx21) and the other in exon 6 (wild-type of E6cluster) in
the 30 end.13,25 This methodology would fail to amplify the
CYP21A2 gene carrying both p.G110fx21 and E6culster
mutations, although thisCYP21A2 gene has not been found yet
in Argentinean,38 Italian,39 Chinese,13 or American30 popula-
tions. Day et al40 suggest that using internal mutation-speciﬁc
primers might yield false-negative results due to preferential
ampliﬁcation or allele dropout; thus, a PCR product with a full
CYP21A2 gene containing the 50 end of theCYP21A2 gene and
the downstream sequence of the TNXB gene is preferable in
CYP21A2 mutation analysis.
We recently described that a signiﬁcant subset (13%) of
patients with 21-OHD CAH suffer from clinical features of
Ehlers-Danlos syndrome due toTNXB haploinsufﬁciency, and
these patients carrying a CYP21A2 deletion had a clinically
signiﬁcant contiguous CYP21A2 deletion that extended into
the TNXB gene.22 Most strategies for CYP21A2 genetic anal-
ysis12,13,21,23 are not able to identify this clinically important
chimera. However, in our strategy, the primer pair, CYP779f
and Tena32F (Figure 2A), is capable of ampliﬁcation of any
CYP21A2, CYP21A1P, or chimeric CYP21A1P/CYP21A2
gene that is closely adjacent to the TNXB gene. Additionally,
by using our strategy, we are able to identify a chimeric TNXA/
TNXB gene,16 which is expected to be dysfunctional due to
a 121-bp deletion shifting the reading frame from the TNXA
gene and resulting in TNXB haploinsufﬁciency.
To our knowledge, this is the ﬁrst direct comparison of
various commonly used methods to analyze the CYP21A2
gene in a large cohort of CAH patients. By combining
existing methodologies and optimizing primer pair choice,
we have established a convenient and comprehensive
approach to the molecular analysis of CAH. We have also
addressed the clinically important issue of identifying
attenuated and tenascin-X affected chimera. This strategy
will provide genetic information that surpasses previously
described strategies and will inevitably aid in clinical care
and genetic counseling of patients affected by CAH due to
21-OHD.751
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